1. Scrip
  2. >>Business

Vertex Under Pressure To Spend On M&A

Company Has $6.7bn In Cash

 
• By Andrew McConaghie

The biotech is growing fast thanks to its success in cystic fibrosis, but is under pressure to be bolder in its business development

Vertex HQ, Boston
Its self-developed CF franchise boosted Vertex's revenues by 50% in 2020, but investors are looking for M&A to provide the next growth platform.

Vertex, one of biotech’s fastest-growing companies thanks to its success in developing ground-breaking cystic fibrosis therapies, grew its revenues by 50% last year to $6.2bn, and is coming under pressure to spend some of its cash pile on M&A.

The company is forecasting around 10% growth this year, based on expansion from its cystic fibrosis triple therapy Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.